Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,621
  • Shares Outstanding, K 27,605
  • Annual Sales, $ 84,510 K
  • Annual Income, $ -60,640 K
  • EBIT $ -109 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.67
  • Price/Sales 0.51
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 751.82% ( +604.01%)
  • Historical Volatility 83.01%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 751.82% on 01/17/25
  • IV Low 28.61% on 07/17/24
  • Put/Call Vol Ratio 0.16
  • Today's Volume 43
  • Volume Avg (30-Day) 471
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 8,215
  • Open Int (30-Day) 7,767

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.79
  • Number of Estimates 2
  • High Estimate -0.75
  • Low Estimate -0.83
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -49.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +10.00%
on 12/23/24
2.3600 -20.76%
on 01/07/25
+0.0500 (+2.75%)
since 12/17/24
3-Month
1.4100 +32.62%
on 11/15/24
2.3600 -20.76%
on 01/07/25
+0.0600 (+3.31%)
since 10/17/24
52-Week
1.3550 +38.01%
on 09/24/24
2.8900 -35.29%
on 07/23/24
-0.0100 (-0.53%)
since 01/17/24

Most Recent Stories

More News
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

FBIO : 1.8700 (-2.09%)
FBIOP : 6.98 (+2.65%)
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

FBIO : 1.8700 (-2.09%)
CKPT : 3.18 (-4.50%)
Fortress Biotech Announces FDA Approval of Emrosi for Rosacea Treatment and Details Upcoming PDUFA for Cosibelimab

Fortress Biotech announced FDA approval for Emrosi for rosacea and a PDUFA date for cosibelimab. Financial results show a net loss.Quiver AI SummaryFortress Biotech, Inc. announced that its product Emrosi,...

FBIO : 1.8700 (-2.09%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 1.8700 (-2.09%)
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO : 1.8700 (-2.09%)
FBIOP : 6.98 (+2.65%)
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FBIO : 1.8700 (-2.09%)
CKPT : 3.18 (-4.50%)
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO : 1.8700 (-2.09%)
DERM : 3.66 (-3.43%)
Journey Medical Corporation Announces U.S. FDA Approval of Emrosiâ„¢ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

FBIO : 1.8700 (-2.09%)
DERM : 3.66 (-3.43%)
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

FBIO : 1.8700 (-2.09%)
DERM : 3.66 (-3.43%)
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

FBIO : 1.8700 (-2.09%)
ATXI : 1.8500 (+5.71%)

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 2.0500
2nd Resistance Point 2.0100
1st Resistance Point 1.9400
Last Price 1.8700
1st Support Level 1.8300
2nd Support Level 1.7900
3rd Support Level 1.7200

See More

52-Week High 2.8900
Fibonacci 61.8% 2.3036
Fibonacci 50% 2.1225
Fibonacci 38.2% 1.9414
Last Price 1.8700
52-Week Low 1.3550

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar